       Document 0619
 DOCN  M9610619
 TI    Diagnostic utility of immune-complex-dissociated p24 antigen detection
       in perinatally acquired HIV-1 infection in Rwanda.
 DT    9601
 AU    Bulterys M; Farzadegan H; Chao A; Dushimimana A; Voltz A; Nawrocki P;
       Kurawige JB; Saah AJ; Department of Epidemiology, School of Hygiene and
       Public Health,; Johns Hopkins University, Baltimore, Maryland, USA.
 SO    J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Oct 1;10(2):186-91.
       Unique Identifier : AIDSLINE MED/96007282
 AB    We evaluated the diagnostic utility and prognostic value of
       immune-complex-dissociated (ICD) HIV-1 p24 antigen detection in a
       prospective cohort study of perinatally acquired HIV-1 infection in
       Butare, Rwanda. HIV-1 p24 antigen was measured after acid dissociation
       in plasma samples collected at 6 weeks and 3 months of age from 36 HIV-1
       infected and 80 uninfected children born to HIV-1 infected women. Among
       children with persistent HIV-1 antibody after 12 months of age, 26.7% of
       samples tested ICD HIV-1 p24 antigen positive. Among children who died
       between 3 and 12 months of age but were classified as HIV-1 infected,
       17.6% tested p24 antigen positive at 6 weeks of age and 33.3% at 3
       months of age. Female infants were more likely to test p24 antigen
       positive than male infants (p = 0.046). The specificity of the assay was
       96.8%. Cumulative probabilities of child survival to 36 months of age
       were computed by HIV-1 status of the child and early p24 antigenemia.
       The mean survival time was 7 months for HIV-1 infected children with a
       high (> 50 pg/ml) p24 antigen concentration versus 20 months for
       children with p24 antigen concentrations between 10 and 50 pg/ml (p =
       0.02). Cumulative probabilities of survival to 36 months of age were 0%
       among HIV-1 infected children with at least one positive p24 antigen
       test, 44% among confirmed HIV-1 infected children who were p24
       antigen-negative at both 6 weeks and 3 months of age, and 95% among
       seroreverting children (p < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)
 DE    Adult  *Antigen-Antibody Complex  AIDS Serodiagnosis/METHODS  Cohort
       Studies  *Disease Transmission, Vertical  Enzyme-Linked Immunosorbent
       Assay  Female  Follow-Up Studies  Human  HIV Antibodies/ANALYSIS  HIV
       Core Protein p24/*BLOOD  HIV
       Infections/*DIAGNOSIS/EPIDEMIOLOGY/TRANSMISSION  HIV-1/*IMMUNOLOGY
       Infant  Infant, Newborn  Male  Pregnancy  Prognosis  Prospective Studies
       Rwanda/EPIDEMIOLOGY  Sensitivity and Specificity  Support, U.S. Gov't,
       P.H.S.  Survival Rate  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

